Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice

  • Vacas Oliva, Eva
  • Arenas Jiménez, María Isabel|||0000-0002-7825-0654
  • Muñoz Moreno, Laura|||0000-0002-2322-8986
  • Bajo Chueca, Ana María|||0000-0002-4944-4222
  • Sánchez Chapado, Manuel Vicente|||0000-0003-3317-4544
  • Prieto Villapún, Juan Carlos
  • Carmena Sierra, María José|||0000-0002-5602-0014
We studied antitumor effect of VIP in human renal cell carcinoma (RCC) (A498 cells xenografted in immunosuppressed mice). VIP-treated cells gave resulted in p53 upregulation and decreased nuclear ?-catenin translocation and NFKB expression, MMP-2 and MMP-9 activities, VEGF levels and CD-34 expression. VIP led to a more differentiated tubular organization in tumours and less metastatic areas. Thus, VIP inhibits growth of A498-cell tumours acting on the major issues involved in RCC progression such as cell proliferation, microenvironment remodelling, tumour invasion, angiogenesis and metastatic ability. These antitumoral effects of VIP offer new therapeutical possibilities in RCC treatment., Ministerio de Ciencia e Innovación, Junta de Comunidades de Castilla-La Mancha, Fundación Mutua Madrileña, Fundación Jesús Serra (Grupo Catalana de Occidente)
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression

  • Vacas Oliva, Eva
  • Muñoz Moreno, Laura|||0000-0002-2322-8986
  • Fernández Martínez, Ana Belén
  • Bajo Chueca, Ana María|||0000-0002-4944-4222
  • Sánchez Chapado, Manuel Vicente|||0000-0003-3317-4544
  • Prieto Villapún, Juan Carlos
  • Carmena Sierra, María José|||0000-0002-5602-0014
Vasoactive intestinal peptide (VIP) decreases cell proliferation through PI3K signalling and prevents tumour progression in clear renal cell carcinoma (RCC). Here we analyzed the signalling pathways that mediate such VIP effects by using human RCC A498 cells. The effects of treatment with 1 mM VIP and/or speci?c protein kinase inhibitors such as H89, Wortmannin and PD98059 were studied by cell adhesion assay, ELISA of VEGF165 and ROS production assays. Semiquantitative RT-PCR and western blot were performed to study p53 expression. VIP increased cell adhesion and ROS production, and decreased VEGF165 secretion through PI3K signalling. Moreover, VIP increased nuclear expression of tumour suppressor p53. VIP effects could be blocked by cell incubation with a speci?c p53 inhibitor, cyclin pi?thrin-a hydrobro- mide (CPFT-?H). In conclusion, this study provides a p53-dependent mechanism by which VIP regulates cell proliferation in RCC development. It supports a potential usefulness of VIP in new therapies of RCC., Ministerio de Ciencia e Innovación, Junta de Comunidades de Castilla-La Mancha, Fundación Mutua Madrileña, Fundación Jesús Serra
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) on Growth and Invasiveness of PC3 Human Prostate Cancer

  • Muñoz Moreno, Laura|||0000-0002-2322-8986
  • Arenas Jiménez, María Isabel|||0000-0002-7825-0654
  • Schally, Andrew Victor
  • Fernández Martínez, Ana Belén
  • Zarka, Elias
  • González-Santander Martínez, Marta|||0000-0002-8901-1077
  • Carmena Sierra, María José|||0000-0002-5602-0014
  • Vacas Oliva, Eva
  • Prieto Villapún, Juan Carlos
  • Bajo Chueca, Ana María|||0000-0002-4944-4222
New approaches are needed to the therapy of advanced prostate cancer. This study determined the effect of growth hormone- releasing hormone (GHRH) antagonists, JMR-132 and JV-1-38 on growth of PC3 tumors as well as on angiogenesis and metastasis through the evaluation of various factors that contribute largely to the progression of prostate cancer. Human PC3 androgen-independent prostate cancer cells were injected subcutaneously into nude mice. The treatment with JMR-132 (10 ug/day) or JV-1-38 (20 ug/day) lasted 41 days. We also evaluated the effects of JMR-132 and JV-1-38 on proliferation, cell adhesion and migration in PC-3 cells in vitro. Several techniques (Western blot, reverse transcription polymerase chain reaction, immunohistochemistry, ELISA and zymography) were used to evaluate the expression levels of GHRH receptors and its splice variants, GHRH, vascular endothelial growth factor (VEGF), hypoxia inducible factor (HIF)-1alpha, metalloproteinases (MMPs)-2 and -9, beta-catenin and E-cadherin. GHRH antagonists suppressed the proliferation of PC-3 cells in vitro and significantly inhibited growth of PC3 tumors. After treatment with these analogues, we found an increase in expression of GHRH receptor accompanied by a decrease of GHRH levels, a reduction in both VEGF and HIF-1alpha expression and in active forms of MMP-2 and MMP-9, a significant increase in levels of membrane-associated ?-catenin and a significant decline in E-cadherin. These results support that the blockade of GHRH receptors can modulate elements involved in angiogenesis and metastasis. Consequently, GHRH antagonists could be considered as suitable candidates for therapeutic trials in the management of androgen-independent prostate cancer., Junta de Comunidades de Castilla-La Mancha, Comunidad de Madrid, Universidad de Alcalá, Ministerio de Ciencia e Innovacion
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095)

  • Sotomayor Núñez, Sandra
  • Muñoz Moreno, Laura|||0000-0002-2322-8986
  • Carmena Sierra, María José|||0000-0002-5602-0014
  • Schally, Andrew Victor
  • Sánchez Chapado, Manuel Vicente|||0000-0003-3317-4544
  • Prieto Villapún, Juan Carlos
  • Bajo Chueca, Ana María|||0000-0002-4944-4222
Bombesin (BN) and gastrin-releasing peptide (GRP) have been shown to stimulate the growth of human prostate cancer in vivo and in vitro by mechanisms initiated by binding of the peptide to BN/GRP receptor (GRPR). GRPR is overexpressed in a variety of human cancers, including human prostatic carcinoma. This led us to evaluate the effectiveness of blocking GRPR and of chemotherapy targeted to GRPR in androgen-dependent (LNCaP) and androgen-independent (PC-3) prostate cancer cells, which exhibit different features of disease progression. Thus, we used a cytotoxic BN/GRP analog, AN-215, consisting of 2-pyrrolinodoxorubicin (AN-201) linked to BN-like carrier peptide, and a BN/GRP receptor antagonist, RC-3095. Semiquantitative RT-PCR and Western blotting revealed that mRNA and protein levels for GRPR increased in prostate cancer cells as compared with nonneoplastic RWPE-1 cells. Immunofluorocytochemistry and Western blot assays revealed that AN- 215 was the most effective analog decreasing both the expression of epidermal growth factor receptor family members and the activation of epidermal growth factor receptor and HER-2, which are associated to a poor prognosis. Furthermore, analogs targeted to BN/GRP receptors, AN-215 and RC-3095, blocked the effect of BN on cell growth in RWPE-1, LNCaP and PC-3 cells. These findings shed light on the mechanisms of action of these analogs and support the view that the use of AN-215 and RC-3095 for blocking BN/GRP receptors for targeted therapy may be of benefit for treatment of advanced prostate cancer., Ministerios de Educación y de Ciencia e Innovación, Comunidad de Madrid, Fundación para la Investigación en Urología